# Nacuity Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nacuity-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Fort Worth, US
- Website: www.nacuity.com
- Total disclosed funding: $17M
- Latest round: Series B (Jun 15, 2022)
- Investors on record: 3

## About

Nacuity Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies to combat oxidative stress related to blinding eye diseases and chronic conditions.Founded in 2016 in Fort Worth, US, Nacuity Pharmaceuticals, Inc. specializes in creating therapies for retinal diseases. The company's founder, Halden Conner, has a background in pharmaceutical development. The company received USD 16.5 mn in Series B funding on June 15, 2022, led by Foundation Fighting Blindness, with other investors including Maxim Group and Retinal Degeneration Fund. This funding marks its latest investment round, bringing the total amount raised to USD 16.5 mn.Nacuity Pharmaceuticals specializes in the development of innovative therapies aimed at addressing oxidative stress, a significant factor in blinding eye diseases and various serious chronic conditions. The core product offerings include targeted prescription therapies for conditions such as retinitis pigmentosa, cataract, and cystinosis. These therapies are designed to halt oxidative tissue damage, providing potential solutions for both rare and prevalent ophthalmic diseases, primarily targeting individuals suffering from retinal diseases and other related conditions. Nacuity's products are primarily marketed in the United States and may extend to other regions where there is a demand for advanced ophthalmic treatments.Nacuity Pharmaceuticals operates on a revenue model that encompasses partnerships and direct-to-consumer sales for its prescription therapies. The company engages with healthcare providers and institutions, facilitating access to its therapies aimed at treating oxidative stress-related diseases. Revenue transactions occur through established agreements with healthcare professionals and institutions that prescribe these targeted therapies to patients. While specific pricing plans for the products are not publicly detailed, the company is expected to implement a structured approach to pricing that reflects the unique value and clinical outcomes associated with its innovative treatments. Nacuity’s flagship products focus on progressive ocular conditions and likely form the basis of its revenue-generating activities in a market that seeks effective solutions for chronic diseases.Nacuity Pharmaceuticals plans to utilize the USD 16.5 mn raised in Series B funding to develop a treatment for retinitis pigmentosa and other serious blinding and chronic diseases caused by oxidative stress. The company is focusing on expanding its product line and aims to enter new markets, with specific plans targeting regions with high unmet medical needs for ophthalmic therapies. The funding will support the research and development of these new therapies, aligning with Nacuity's strategic growth initiatives.

## Funding rounds

- Series B, Jun 15, 2022, $17M — Maxim Group, Foundation Fighting Blindness, Retinal Degeneration Fund

## Investors

- Maxim Group — Series B
- Foundation Fighting Blindness — Series B
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series B